Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

Novartis gets good news on cancer drug Afinitor

July 5, 2011

ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.

Medicare will keep covering Roche's Avastin

June 30, 2011

WASHINGTON (Reuters) - Medicare will continue coverage of Roche Holdings' drug Avastin for breast cancer regardless of what U.S. health regulators decide about the medicine, a spokesperson for the U.S. health insurer said.

Roche undeterred after FDA's Avastin rebuff

June 30, 2011

ZURICH (Reuters) - Swiss drugmaker Roche Holding AG had nothing to lose by giving Avastin another roll of the dice, and by doing so showed the world it still believes the drug should be used in breast cancer.

US FDA panel rejects Avastin for breast cancer use

June 29, 2011

SILVER SPRING, Md. (Reuters) - U.S. health advisers delivered a blow to Roche Holding on Wednesday, voting to reject the use of Roche Holding drug Avastin for breast cancer while the Swiss drugmaker conducts more studies.

FDA Invites Comments on Avastin

May 11, 2011

FDA officials have invited the public to testify at a hearing that will argue the merits of bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer.

NCCN Updates Metastatic Guidelines

April 5, 2011

The National Comprehensive Cancer Network’s updated clinical practice guidelines for metastatic breast cancer retain bevacizumab as a treatment option and add two new therapies, the chemotherapy medicine eribulin and the RANKL inhibitor denosumab.

FDA Grants Avastin Hearing

March 15, 2011

FDA has agreed to Genentech’s request to revisit the agency’s decision to withdraw bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer. A public hearing is scheduled for June 28-29, and the resultant ruling is final.

Company Requests Hearing for Avastin

January 18, 2011

Roche/Genentech, maker of Avastin (bevacizumab), has requested a hearing before the U.S. Food and Drug Administration to appeal the agency’s December 2010 decision to withdraw approval of bevacizumab as a treatment for metastatic breast cancer.

Avastin raises heart failure risk in breast cancer

January 4, 2011

CHICAGO (Reuters) - Women with advanced breast cancer who were treated with Roche's Avastin were more likely to develop heart failure than other women, according to an analysis released on Tuesday that raised more concerns about the already troubled drug.

Women Respond to FDA Ruling on Avastin

December 23, 2010

Women with metastatic breast cancer share how they feel about FDA’s decision to rescind approval of bevacizumab (Avastin) as a treatment for metastatic breast cancer.

Denver, CO  ·  September 13, 2014

Join Your Community for Yoga on the Steps!

Close
close